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 Abstract: In the past decades drug discovery practice has escaped from the complexity 
of the formerly used phenotypic screening in animals to focus on assessing drug effects 
on isolated protein targets in the search for drugs that exclusively and potently hit one 
selected target, thought to be critical for a given disease, while not affecting at all any 
other target to avoid the occurrence of side-effects. However, reality does not conform 
to these expectations, and, conversely, this approach has been concurrent with increased 
attrition figures in late-stage clinical trials, precisely due to lack of efficacy and safety. 
In this context, a network biology perspective of human disease and treatment has burst 
into the drug discovery scenario to bring it back to the consideration of the complexity 
of living organisms and particularly of the (patho)physiological environment where 
protein targets are (mal)functioning and where drugs have to exert their restoring action. 
Under this perspective, it has been found that usually there is not one but several 
disease-causing genes and, therefore, not one but several relevant protein targets to be 
hit, which do not work on isolation but in a highly interconnected manner, and that most 
known drugs are inherently promiscuous. In this light, the rationale behind the currently 
prevailing single-target-based drug discovery approach might even seem a Utopia, 
while, conversely, the notion that the complexity of human disease must be tackled with 
complex polypharmacological therapeutic interventions constitutes a difficult-to-refuse 
argument that is spurring the development of multitarget therapies. 
 
Keywords: Network pharmacology, Polypharmacology, Multitarget therapies, Protein 
interaction networks, Multitarget drugs. 
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1. INTRODUCTION 
Two important issues in drug discovery programs are the intended pharmacological 
profile of drugs to be developed and the way their pharmacological profiling is carried 
out. Several decades ago, drug candidates were subjected to phenotypic 
pharmacological profiling in animal models to determine their efficacy and safety under 
the complex physiological or pathophysiological conditions, without paying much 
attention to the key molecular details of the interaction (affinity / selectivity) of the drug 
molecule with its potential protein targets. Indeed, physiological responses to drugs 
were monitored with minimal assumptions regarding the participation of specific 
molecular targets and/or signaling pathways [1]. Moreover, because the results of these 
in vivo studies were the consequence of a number of complex pharmacokinetic and 
pharmacodynamic processes, they were rather difficult to be interpreted thereby 
rendering it difficult any attempt to establish structure-activity relationships for 
increasing affinity and/or selectivity for any putative biological target.  
Recent advances in molecular and structural biology technologies that allowed isolation 
and characterization at the atomic level of protein targets and protein target-drug 
interactions [2] as well as the assumption that a particular disease is caused by an 
abnormality in one disease-causing gene and in the protein it encodes, has prompted  a 
search for simplicity in drug discovery programs in the last three decades: now drugs 
effects are studied in a simpler scenario as the pharmacological profiling of drugs is 
carried out in vitro on isolated protein targets, thus disregarding the 
(patho)physiological environment of the latter. Thus, the one-disease, one-gene, one-
protein, one-drug philosophy constitutes the rational basis of the so-called reductionist 
approach of drug discovery, which is the most prevailing paradigm of current rational 
drug design both in pharmaceutical companies and in academy [3]. In the early steps of 
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the drug discovery process the pharmacological profile of new investigational 
compounds is established by subjecting them to a number of in vitro tests against the 
particular isolated protein target, considered critical for the disease, that is expected to 
be hit by the studied compounds, and a number of other isolated related targets that are 
expected not to be hit by those compounds [3,4].  
Regarding the intended pharmacological profile of drugs, now affinity and selectivity of 
drugs toward protein targets do matter. Working on isolated targets, the structural 
determinants of the interaction of a drug with the studied molecular targets can be 
readily dissected, thereby making it feasible the optimization of affinity and selectivity 
toward the desired target. The final aim of this reductionist approach is obtaining highly 
potent and exquisitely selective drugs that are only active against the critical protein 
target to be hit for treating a particular disease while remaining inactive against any 
other target, whose modulation is thought to inexorably lead to the occurrence of 
unwanted side-effects [5], thereby fulfilling the philosophy of Paul Ehrlich about 
“magic bullets” [6] and leading to safer and more effective drugs. With these premises, 
interaction of a compound with several protein targets, i.e. polypharmacology, has 
traditionally been perceived negatively, as an undesirable property, inasmuch as it has 
been thought to be necessarily accompanied by toxicity [7], and those compounds that 
hit multiple targets are labeled with the pejorative terms of “promiscuous drugs” or 
“dirty drugs”. 
In this context, drug discovery programs were expected to be fuelled by the discovery of 
new disease-causing genes and their encoded proteins to be targeted by drugs. Thus, 
deep mining of the human genome was expected to provide drug discovery pipelines 
with a huge number of potential novel drug targets [1,8], thereby increasing the drug 
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target space, and the potential for development of innovative drugs, and expanding the 
opportunities for increased pharmaceutical productivity and revenues.  
Indeed, 480 new targets for small molecule drugs have been estimated yet to be mined 
from the human genome [8], whereas currently known drugs are estimated to hit 500 
different molecular targets [3,9]. However, the increase in novel drug targets has been 
relatively slow after sequenciation of the human genome [10,11].  
Not only has the target-based reductionist approach not benefited from a significant 
increase in the number of novel targets but also its impact on the number of new 
approved drugs and on the emergence of efficacious and safe treatments has not 
fulfilled the expectations. Indeed, overall pharmaceutical productivity, as estimated by 
the rate of drug launches, has been falling since the 1970s [12], and in the past decade 
target-based drug discovery approaches have led to a significantly lower discovery rate 
of FDA-approved first-in-class new molecular entities than programs based on 
phenotypic screening [13]. Overall, concurrent with the prevailing notion that 
exquisitely selective drugs should be developed, the approval rate for new drugs has 
been declining despite the huge increase of global investment in drug discovery and 
development by pharmaceutical industry [14-18]. Lack of efficacy and toxicity account 
for 60% of failures during the clinical testing of novel drug candidates, they 
representing the two main causes of clinical attrition in late-stage drug development 
[19]. Particularly, the lack of efficacy of many promising drug candidates that have 
failed in late-stage clinical trials has been ascribed either to the impossibility of finding 
a single critical molecular target to efficaciously tackle complex diseases [14], or to the 
selection of a target that resulted not to be critical for the pathophysiology of the disease 
[20], or to an inappropriate choice of in vitro cellular models for predicting off-target 
effects [18].  
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As a consequence, after having followed the reductionist approach for nearly three 
decades, efficacious treatments for many highly prevalent diseases still remain elusive 
[21], which puts considerable pressure on healthcare systems [8]. 
The decrease in complexity when shifting from drug discovery approaches based on 
phenotypic screening to the isolated single protein target-based reductionist approach 
has also led to a decrease in relevance to the human condition [22], because proteins 
rarely function in isolation under (patho)physiological conditions but they do interact 
with other proteins, operating as part of highly interconnected cellular networks 
[11,23,24]. 
The notion that drug targets do not have to be considered in isolation but that they 
should be taken back to their complex physiological context is increasingly gaining 
adepts. Indeed, protein targets which are critical for a disease and exhibit one-to-one 
genotype-pathological phenotype mapping seem to be rare, and diseases are rather 
caused by the dysfunction of a dynamic network of interacting proteins [3]. 
Consequently, a new paradigm of drug discovery is emerging, the so-called network 
pharmacology, which considers both the complexity of disease states and also protein 
targets and drug-target interactions at the molecular level with the final aim of deriving 
polypharmacological therapies capable of targeting disease-associated network states by 
simultaneously interacting with multiple relevant targets of a complex disease network 
rather than individual protein targets alone [19]. 
 
2. THE COMPLEX ENVIRONMENT OF DRUG TARGETS 
 
Proteins, in general, and drug target proteins in particular, are not alone in the 
physiological context but they are rather “social” molecules [25]. Proteins and other 
endogenous macromolecules are inside cells in a very high concentration, physically 
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occupying up to a 40% of the total volume [26]. Under the resulting “macromolecular 
crowding” many cellular processes that result in increased available volume inside the 
cell, such as protein folding, protein aggregation and also protein interactions, are 
stimulated [26-28]. In this light, it can be easily inferred that proteins are prone to 
associate and interact within biological systems. Indeed, in living organisms proteins as 
well as other basic macromolecules such as nucleic acids are interconnected, forming a 
complex network of interactions that allows a continuous flux of information necessary 
for most cellular functions and eventually for their viability and functionality [17,23]. 
Changes that distort the equilibrium of this physiological network lead to a new 
network, the pathological network [5,19,23,29-31]. The interactions between proteins 
and other cellular components, rather than the individual proteins, are the real 
determinants of the behavior of the (patho)physiological system [32]. Thus, diseases 
should be regarded as disturbed interaction networks rather than alterations of a single 
“critical” molecular component [17]. 
Both physiological and pathological networks seem to be stable and robust, as they are 
resilient to attacks and perturbations. The robustness of biological systems has been 
clearly demonstrated in large-scale functional genomics studies, where single-gene 
knock-out experiments in a variety of model organisms have been found to have only 
little or no effect at all on their phenotypes [19]. Different mechanisms seem to account 
for the robustness of biological systems, particularly the existence of alternative or fail-
safe mechanisms where similar (redundancy) or different (diversity) components and 
modules of the network with overlapping functions can replace some particular 
components that are failing [33,34]. Thus, selective inhibition of an individual protein 
target of a pathological network by a drug might lead to the activation of multiple 
redundant or alternative pathways, thereby bypassing the inhibitory effect of the drug 
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and resulting in clinical relapse [23,33,35-37]. Conversely, modulation of multiple 
nodes within a biological network would be rather required to achieve any phenotypic 
modification [5]. 
Consideration of diseases as complex inherently robust protein interaction networks that 
might be vulnerable through modulation at sensitive nodes [23] has immediate 
implications for drug discovery. As diseases are complex, they require complex 
therapeutic approaches that should target not single proteins but imbalances of multiple 
proteins within an interaction network [5,17,19,20,29,30,34,38,39]. In this light, it 
becomes apparent that exquisitely selective drugs designed as “magic bullets” in the 
frame of the reductionist approach might easily exhibit lower-than-needed efficacy, 
which might in a great part account for the high attrition figures in clinical trials during 
the past decades. On the contrary, network pharmacology involving 
polypharmacological therapeutic interventions that selectively hit multiple relevant 
protein targets within the pathological network as “magic shotguns”, emerges as a 
realistic alternative drug discovery approach that should derive treatments with greater 
clinical efficacy [4,5,7,17,19,29,39-44]. 
Not only may multiple-target therapeutic interventions afford greater efficacy but they 
may also lead to increased safety. Because most components of biological networks 
seem to be weakly and transiently linked with each other, a therapeutic intervention 
intended to simultaneously modulate multiple points of a pathological network will 
likely not require a high potency but a low-affinity interaction at each single target [29], 
so that drug doses can be reduced thereby circumventing or minimizing the occurrence 
of dose-related side-effects [39]. Moreover, low potency modulation of several targets 
of the network will likely not trigger large homeostatic processes associated with the 
appearance of side-effects, which, conversely, can be promoted by highly target-specific 
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drugs [45]. Besides, it has been even suggested that partial inhibition of several targets 
can be not only safer but also more efficient than complete inhibition of a single target 
[29] 
Selection of the multiple points to be hit within a pathological network for an optimal 
therapeutic intervention requires the knowledge of its detailed protein interaction map. 
Construction of protein interaction networks usually involves an iterative integration of 
experimental and computational methodologies [38,46-48]. A first draft of the 
interactome network can be built on the basis of literature data, by collecting 
information about the molecular components of the network and the relationships 
among them. Then, the components and structure of the model are refined by subjecting 
its molecular components to large-scale genetically-, biologically- and/or chemically-
induced perturbations and observing the experimental responses (monitoring of gene 
translation, protein expression, and signaling events, identification of interactions 
patterns, etc.) to such perturbations. Alternatively, these costly and time- and effort-
consuming large scale genomics, proteomics and metabolomics experimental 
methodologies can be replaced by computational methods that have been developed for 
predicting protein-protein interactions and constructing interactome models [49-53]. 
Finally, once a stable network model of a given disease is available, analysis of the 
topological and dynamic properties of the pathological network will shed light on the 
molecular mechanisms underlying the pathological process and will allow us to identify 
some potential biomarkers as well as the optimal combination of targets to be hit by the 
therapeutic intervention for achieving a maximal modulation of the disease while 
avoiding redundancies that might neutralize the effects of such intervention [32] and 
minimizing the appearance of side-effects [19,38,54]. Worthy of note, not only should 
the network positioning of nodes be considered in the selection of the combination of 
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protein targets to be hit, but also their druggability is an essential issue. Indeed, it has 
been estimated that only 10-15% of the protein components of disease-associated 
protein interaction networks are amenable for being targeted by small molecule drugs 
[19]. 
Advances in high throughput screening and “omics” methodologies, particularly 
genomics, transcriptomics, proteomics and metabolomics, are allowing us to unveil a 
great number of protein interactions in a number of model organisms [40,55-60]. 
Important endeavors are also being done for charting the human protein-protein 
interaction network [61-63], even taking into account the 3D structures of the 
interaction partners (3D interactome networks) [25], as well as the interactome networks 
of human diseases (Fig. 1) [32,63-67], although there is still much to be done [68]. 
 
Fig. (1). Artistic representation of the protein interaction network underlying 
alzheimer’s disease [64]. Image created by Dr. Roberto Mosca (IRB, Barcelona). 
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3. COMPLEXITY OF DRUGS, DRUG TARGETS AND DISEASE-CAUSING 
GENES RELATIONSHIPS 
Consideration that human diseases are caused from an abnormality in a single gene, 
selection of a given protein target which is critical for a particular disease, and design of 
drugs that hit that protein target with high affinity and selectivity under the frame of the 
currently prevailing reductionist drug discovery paradigm not only may fall short of 
deriving efficacious and safe treatments but these notions themselves are overly 
simplistic and not accurate.  
On the one hand, human diseases are increasingly being found to have several causative 
factors, and even several genetic diseases that were assumed to be caused by mutations 
on a single gene have resulted to involve several causative genes. Moreover, the 
multiple disease-causing genes of many diseases seem to work together in the same 
biological module or pathway, their encoded proteins having an increased tendency to 
interact between them, thereby supporting again the conception of diseases as 
pathological networks [32,69]. 
On the other hand, it has been found that a particular protein target can be hit by a 
number of drugs with different chemical structures and even with different therapeutic 
indications [11,70], a fact that can be understood taking into account that protein targets 
are often involved in multiple diseases [4].  
Finally, many known drugs have been retrospectively found to be able to hit multiple 
biological targets, even if they were designed to be selective against a particular target 
[5,19,71,72]. Indeed, the presence of polypharmacological profiles in known drugs 
seems to be the rule rather than the exception [3,11,45].  Overall, it has clearly emerged 
a much more complex picture of the relationships among drugs, protein drug targets and 
disease-causing genes than initially thought. 
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Pretensions to develop target-specific drugs may seem counterintuitive if it is taken into 
account that: i) the site of action of drugs in the organism is very complex, with many 
potential interaction partners (proteins, nucleic acids, carbohydrates, metabolites, etc.) 
and ii) the fact that most drugs are relatively small molecules, and therefore they might 
be reasonably expected to interact with more or less affinity with more than one 
intended molecular target among the high number of potential endogenous molecules 
they may find in the way to their site of action. Recent analysis of drugs-drug targets 
interactions has suggested that on average each drug interacts with 6 known molecular 
targets [73,74]. A serendipitous match of appropriate biological targets and affinities 
toward these targets of a successful known drug might account for its clinical efficacy, 
whereas a mismatch of some of the targets hit by the drug and/or the potency at which 
they are hit might be responsible for the lower efficacy of other drugs or the lack of 
efficacy and safety of many recent drug candidates that failed in clinical trials. 
Interaction of a drug with unexpected molecular targets may certainly lead to undesired 
side-effects but, very interestingly, also to a higher clinical efficacy [45]. Indeed, the 
apparent multitarget profile, and therefore promiscuity, of known drugs, seems to 
directly account for the clinical efficacy of many drugs, notably in therapeutic areas 
such as cancer and central nervous system diseases [5,39,40,45,75-78]. It has been 
suggested that drugs of the same therapeutic class and similar clinical efficacy might 
share a similar pattern of multitarget effects. The study of the drug-drug targets 
interaction network within a class of drugs might be very useful for unraveling 
unforeseen important components of their therapeutic mechanism [72] and for charting 
the coverage maps including the protein targets shared by all the members of the class, 
which in principle should be considered as responsible for their clinical efficacy [45]. 
These coverage maps might be used as templates for further optimization of multitarget 
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therapeutic interventions, but always keeping in mind the possibility of “false positives” 
(protein targets shared by all drugs of the class and not linked to clinical efficacy but to 
side-effects) or “false negatives” (targets non shared by all of the drugs of the class but 
relevant for individual differences in clinical efficacy) [45]. 
Some prominent examples of well-known efficacious drugs whose retrospectively 
established multitarget profile seems to be responsible for their clinical efficacy are 
briefly discussed below. 
Imatinib (Gleevec®), the first anti-cancer kinase inhibitor to be marketed, was purposely 
designed and regarded as a paradigm of “magic bullet”, i.e. as an exquisitely selective 
drug that was expected to act on a single aberrant protein expressed in tumor cells, 
namely the activated p210BCR-ABL tyrosine kinase [79], for specifically killing tumor 
cells without harming healthy cells. However, soon thereafter it was found that imatinib 
is not at all as selective as initially thought as it could also interact with other protein 
targets such as the platelet-derived growth factor receptor (PDGF-R) and c-kit [80,81], 
among other kinases [82], its multikinase inhibitor profile directly accounting for its 
outstanding clinical efficacy [77,80,83]. These results prompted the development of 
other compounds with multikinase inhibitor profile and several of them are being 
already successfully used in the clinics, namely sunitinib, dasatinib, erlotinib, gefitinib, 
lapatinib, and sorafenib, whereas many others are undergoing clinical testing. Not only 
have these drugs higher clinical efficacy than classical cytotoxic chemotherapeutic 
drugs, but they also exhibit a better safety profile [84]. As a class, these anti-cancer 
kinase inhibitor drugs seem to have quite different profile regarding both the number 
and the type of the different kinases they target, with some of them being considered 
more promiscuous (for example, imatinib, sorafenib and sunitinib) than others (for 
example, erlotinib and gefitinib) [84]. Recently, Karaman et al. have carried out the 
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most comprehensive study of kinase inhibitor selectivity to date by testing a set of 38 
kinase inhibitors on a panel of 317 kinases, which represent more than 50% of the 
predicted human kinome [82]. This study confirmed that kinase inhibitors do clearly 
have propensity to display a multitarget profile and that currently marketed anti-cancer 
kinase inhibitors have different coverage maps, in terms of both number and type of 
targeted kinases. Particularly, the number of kinases targeted by the FDA-approved 
anti-cancer kinase inhibitor drugs with dissociation constant (Kd) values lower than 3 
M ranged from 3 kinases for lapatinib to 165 kinases for sunitinib, whereas for Kd 
values lower than 100 nM the number of targeted kinases ranged from 2 kinases for 
gefinitib to 53 kinases for sunitinib [82] (Fig. 2). As an illustration of the different 
coverage maps of these class of drugs, in Fig. 3 the different kinases targeted by 
imatinib and sunitinib with Kd values lower than 100 nM are shown. The different 
coverage maps of these drugs may explain some differences in their therapeutic profiles 
and the distinct types of cancer they are indicated for, as well as the fact that the more 
promiscuous sunitinib and dasatinib are useful in some types of cancer which are 
resistant to imatinib. 
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Dasatinib
82 kinases with Kd  < 3  M
46 kinases with Kd  < 100 nM
Erlotinib
44 kinases with Kd  < 3  M
4 kinases with Kd  < 100 nM
Gefitinib
21 kinases with Kd  < 3  M
2 kinases with Kd  < 100 nM
Sorafenib
52 kinases with Kd  < 3  M
14 kinases with Kd  < 100 nM
Imatinib
19 kinases with Kd  < 3  M
9 kinases with Kd  < 100 nM
Sunitinib
165 kinases with Kd  < 3  M
53 kinases with Kd  < 100 nM
Lapatinib
3 kinases with Kd  < 3  M
3 kinases with Kd  < 100 nM  
 
Fig. (2). Structures and number of kinases targeted with Kd < 3 M and 100 nM by 
marketed anti-cancer kinase inhibitor drugs. 
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 ABL1: 12 nM DDR1: 0.7 nM LCK: 40 nM 
ABL2: 10 nM DDR2: 15 nM PDGFRA: 31 nM 
CSF1R: 19 nM KIT: 14 nM PDGFRB: 14 nM 
 
 AAK1: 11 nM CLK2: 20 nM FLT3: 0.47 nM MAP4K5: 41 nM PDGFRB: 0.075 nM RPS6KA5: 28 nM 
AMPK-α1: 19 nM CLK4: 29 nM FLT4: 50 nM MERTK: 26 nM PHKG1: 5.5 nM SgK085: 15 nM 
AMPK-α2: 89 nM CSF1R: 2 nM GAK: 20 nM MLCK: 23 nM PHKG2: 5.9 nM SLK: 56 nM 
ARK5: 48 nM CSNK1D: 15 nM ITK: 13 nM MST1: 19 nM PIP5K2B: 39 nM STK33: 17 nM 
AXL: 9 nM CSNK1E: 13 nM JAK1: 49 nM            MST2: 56 nM PTK2B: 82 nM TNIK: 25 nM 
BIKE: 5.5 nM CSNK2A1: 81 nM KIT: 0.37 nM MST3: 63 nM RET: 12 nM TTK: 63 nM 
BLK: 65 nM DAPK3: 22 nM LKB1: 38 nM MYLK2: 49 nM RIOK1: 35 nM TYRO3: 49 nM 
CAMK2A: 80 nM DRAK1: 1 nM LOK: 19 nM PAK3: 16 nM RPS6KA2: 17 nM VEGFR2: 1.5 nM 
CLK1: 22 nM FLT1: 1.8 nM MAP4K1: 16 nM PDGFRA: 0.79 nM RPS6KA4: 96 nM        
 
Fig. (3). Kinases targeted by imatinib and sunitinib with Kd < 100 nM. 
 
Another example of extraordinarily promiscuous drug is clozapine (Clorazil®, Fig. 4), 
the prototype of atypical antipsychotic drugs, which are among the most widely 
prescribed neuropsychiatric drugs [40,85]. The clinical superiority of atypical versus 
typical antipsychotics has been thought to result from a multitarget action on a number 
of postsynaptic biogenic amine G-protein-coupled receptors (GPCRs) [40]. Because a 
precise knowledge of the multitarget coverage map of clozapine is essential for enabling 
the design of optimized antipsychotic drugs, recently Yadav et al. have assessed the 
complex polypharmacological profile of clozapine by evaluating its activity against a 
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panel of 2395 molecular targets, belonging to the GPCR, kinase, transporter, ion 
channel and enzyme classes [86]. By using a combination of experimental and 
chemoinformatic methods [87,88], they found that clozapine, as well as another atypical 
antipsychotic drug, namely olanzapine, interacts potently with a unique set of biological 
targets, different from those targeted by the typical antipsychotic drug haloperidol, 
mainly involving higher affinity interactions with most human serotonin receptors and 
most muscarinic receptors and relatively lower affinity interactions with some 
dopamine receptors (Fig. 4). Within the complex coverage map of clozapine and 
olanzapine, the presynaptic component of the serotonin neuronal system has been 
identified as an essential mediator of their unique atypical antipsychotic action [86]. 
Thus, this presynaptic effect must be present together with a multitarget action at a 
plethora of postsynaptic receptors in the polypharmacological profile of next 
generations of antipsychotic drugs. 
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5-HT1A  1.05   
5-HT1B 3.98 5.09 1.65 
5-HT1E 9.66   
5-HT2A 0.13 0.03 0.73 
5-HT2C 0.29 0.24  
5-HT6 0.17 0.06  
5-HT7 0.18 1.05 3.78 
D1 1.89 0.58 0.83 
D2 4.31 0.72 0.02 
D3 6.46 0.63 0.12 
D4 0.39 0.19 0.15 
D5 2.35 0.90 1.47 
H1 0.02 0.05  
H2 1.53 0.44  
H4 8.20   
α1A 0.02 1.09 0.12 
α1B 0.07 2.63 0.08 
α2A 1.42 3.14  
α2B 0.27 0.82 4.80 
α2C 0.34 0.29 5.50 
M1 0.14 0.24  
M2 0.14 0.79  
M3 0.25 0.51  
M4 0.29 9.98  
M5 0.94 0.09 6.57 
5-HT3 2.41 2.02  
CHK2 1.99   
 
 
Fig. (4). Structure and multitarget profile of the atypical antipsychotic drugs clozapine 
and olanzapine compared with that of the typical antipsychotic drug haloperidol. 
 
The successful antiepileptic drug levetiracetam (Keppra®) was developed as a selective 
modulator of the synaptic vesicle protein 2A (SV2A) [17,89,90], and, indeed, 
optimization of the affinity at this single target led to the development of the more 
potent drug brivaracetam [91], which was considered a successful application of rational 
drug design in the frame of the reductionist approach. However, levetiracetam does not 
act specifically on this target, but it also hits a number of other molecular targets and 
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events such as high-voltage activated calcium channels, delayed rectifier potassium 
current, calcium release from endoplasmic reticulum via the ryanodine, and the IP3 
receptors, hippocampal protein expression and inflammation-impaired resting potential 
of astroglia (Fig. 5) [17]. It has been suggested that other antiepileptic drugs also exhibit 
multitarget profiles that mainly encompass modulation of several ion channel classes 
and that this promiscuity constitutes an important mechanistic clue to seizure treatment 
[41,92,93]. 
 
Levetiracetam
N
O
NH2
O
SV2A
Kd = 0.78 M
Reduction of potassium currents
IC50  (guinea pig) = 47 M
IC50  (rat) = 6 M
Inhibition of high voltage-activated 
calcium channels
IC50  = 14.7 M
Blockade of IP3-dependent calcium release 
induced by bradykinin and ATP
IC50 (bradykinin) = 0.39 M
IC50 (ATP) = 0.20 M
Inhibition of GABA-gated currents
EC50 = 204 M
Reversal of zinc inhibition of glycine 
receptor-mediated responses
EC50 (spinal cord neurons) = 0.7 M
EC50 (hippocampal neurons) = 0.04 M
Inhibition of paroxysal depolarization shifts 
IC50 = 180 M
 
 
Fig. (5). Structure and multitarget profile of the antiepileptic drug levetiracetam. 
 
4. POLYPHARMACOLOGICAL THERAPEUTIC OPPORTUNITIES 
The conception of human diseases as complex pathological networks of interconnected 
proteins and the emergence of network pharmacology as a novel paradigm in drug 
discovery with a promising potential for deriving more efficacious and safer treatments 
have spurred important endeavors for deciphering the complexity of disease networks 
and of the polypharmacological profiles of most known drugs, with the final aim of 
enabling new therapeutic opportunities. These endeavors encompass either using the 
multitarget coverage maps of old drugs as the starting point for finding new therapeutic 
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indications for these drugs or for designing derivatives thereof with modified profiles 
and different indications or for developing different types of multitarget therapeutic 
interventions involving either the simultaneous administration of several drugs or one 
single multitarget drug. These strategies will be only briefly discussed herein, as they 
will be presented in more detail in other articles of this issue [94-104]. 
 
4.1. Drug Repositioning 
The proven facts that drugs usually act on multiple targets and that many protein targets 
appear to be relevant to several diseases provide the rational basis for the so-called drug 
repositioning or drug repurposing, a strategy aimed at finding new therapeutic 
applications for already approved drugs or even for drug candidates that did not reach 
the clinic for a particular indication from the knowledge of their multiple targets 
[96,105-109]. Assessment of the multitarget profile of known drugs can be carried out 
by extensive biological profiling and by application of computational methods 
[17,19,75,88,110-114]. Also, based on the rationale that drugs with a similar side-
effects profile should have a common mechanism of action, the study of the 
relationships known drugs–diseases and known drug–side-effects has been proposed as 
the starting point for finding new therapeutic indications for drugs with similar side-
effects profiles [113,115]. 
Drug repositioning is emerging as rapid, low-risk, and cost-effective strategy of drug 
development, inasmuch is it usually starts from approved drugs, whose 
pharmacodynamic, pharmacokinetic, toxicological and galenic profiles are appropriate 
and perfectly established, thereby significantly reducing the risks associated to drug 
development and facilitating repositioned drugs to enter clinical trials more rapidly and 
less costly than in the case of novel drugs [109,115,116]. 
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 4.2. Selective Optimization of Side Activities 
The multitarget profile of a known drug sometimes does not allow its direct 
repositioning for a new therapeutic indication and it has to be modified in such a way 
that initial low affinity interactions with some targets are optimized whereas initial high 
affinity interactions with other targets are minimized or abolished, so that the resulting 
coverage map is more suitable for the new therapeutic indication.  
This selective optimization of side activities, the so-called SOSA approach [117-119], 
involves an initial screening of a library of known drugs followed by optimization of 
selected hits by a classical medicinal chemistry work, i.e. structural modification of the 
selected drugs to change the pharmacological profile as desired. Even though the safety 
and pharmacokinetic profiles of the drug analogs resulting from the optimization 
procedure are not known, the likelihood that these analogs will still exhibit druglike 
properties and therefore that will be suitable for further development is much higher 
than if the initial hits were not drugs safely used in humans but compounds with poor or 
unknown safety and bioavailability. Worthy of note, because the final analogs that have 
been optimized for the new therapeutic indication can be structurally quite different 
from the parent drug, and therefore structurally original, they may easily be out of the 
scope of the patents of the original drug and therefore patentable by themselves. 
 
4.3. Multitarget Therapies 
The logic behind network pharmacology inescapably leads to polypharmacological 
therapeutic approaches, i.e. the use of one drug or a combination of drugs to 
simultaneously hit several relevant protein targets of the disease network, as the most 
viable way to restore the physiological network state. This can be accomplished either 
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by using combinations of two or more drugs each contained in a separate medicine 
(drug cocktails, polypharmacy) or in a single medicine (fixed-dose combinations 
(FDCs)), or by using single drugs with inherent or purposely designed ability to hit 
those selected multiple targets (multitarget drugs (MTDs)). 
Use of combination therapies, classically drug cocktails and more recently FDCs, 
clearly represents the most established polypharmacological approach, it being a 
standard practice for the treatment of a number of diseases such as cancer, hypertension, 
atherosclerosis, diabetes, asthma, epilepsy, depression, anxiety disorders, AIDS, 
infectious diseases or pain therapy, among others [7,19,120]. Their main advantage is 
related with the possibility of dose flexibility [7,21], which is a very important issue for 
the optimal balance of potencies with which the different molecular targets need to be 
hit. This is especially feasible in drug cocktails, where each medicine can be 
administered at the needed dose, which might be even changed during patient 
monitoring, thereby allowing a change of the molecular ratio of the different drugs of 
the combination during the treatment. Dose flexibility in FDCs is lower because the 
molecular ratio of the different component drugs is by definition fixed when the 
medicine is formulated, but at least molecular ratios different from one-to-one between 
the different drugs are possible.  
The multidrug nature of drug cocktails and FDCs, which may be advantageous for dose 
flexibility, turns into a disadvantage when considering other important issues, namely i) 
the occurrence of drug-drug interactions that might accelerate or reduce the metabolism 
of some of the component drugs, which added to the different relative rates of 
metabolism of the component drugs between patients due to genetic polymorphism and 
to the likely inherent promiscuous profile of each component drug, will lead to 
unexpected and complex pharmacokinetic and pharmacodynamic relationships and to 
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unpredictable variability of effect between patients [21]; ii) the need for more complex 
and expensive clinical trials and more strict regulatory requirements, as efficacy and 
safety has to be demonstrated for each component drug separately and in combination 
[19,121,122]; iii) a reduced molecular target space, as most drug combinations involve 
the use of already known drugs, and therefore a reduced potential for innovation [19]; or 
iv) increased potential for side-effects derived from the addition of the side-effects of 
each component drug [123]. 
Indeed, a major disadvantage of drug cocktails and FDCs is the risk of drug-drug 
interactions. This risk is so significant that the use of drug cocktails has been also 
proposed for a completely different use, namely as a screening tool for the 
characterization of potential in vivo drug-drug interactions to discard drug candidates 
with unacceptable drug interaction profile in the early phases of the drug discovery 
process [124]. Some experimental and theoretical methods are being developed for 
designing optimal drug combinations for therapeutic use, with minimized problems 
associated with drug-drug interactions [76,125-128]. 
The main particularity of drug cocktails, which clearly differentiates them from the 
other strategies, is their multi-medicine or polypharmacy nature, which leads to very 
important drawbacks such as poor patient compliance and inappropriate drug use [123]. 
These issues can be circumvented by the single-medicine approaches (FDCs and 
MTDs), which involve simpler dosing regimens and better treatment adherence 
[123,129,130]. 
A particular issue of FDCs is related with the galenic difficulties that can be found in 
the co-formulation of several drugs into a single medicine, mainly derived from the 
chemical stability and potential chemical or physical interactions between component 
drugs in the combination [120,131]. Worthy of note, development of FDCs has not been 
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devoid of some criticism of commercial opportunism, as in some cases it might be 
driven by factors other than scientific or clinical innovation, for example extension of 
patent protection of a blockbuster drug going off patent by introducing it into a new 
FDC (“evergreening”) or introduction of a new drug, which might be hazardous or 
inefficacious, together with one or more already marketed drugs into a new FDCs 
(“bundling”) [122]. Also, some uncertainty about the clinical efficacy and safety of 
component drugs of a FDC may exist in particular cases which involve the concurrent 
development of two or more new unmarketed drugs into a combination, the so-called 
codevelopment [35,132]. According to a recent FDA guidance codevelopment should 
be restricted for combinations of new drugs against difficult-to-treat diseases, for which 
there are both compelling biological rationale and preclinical or short-term clinical 
results that support the superiority of the combination relative to the component drugs 
alone, and for cases where individual drugs cannot be developed individually [132]. 
Overall, the best polypharmacological treatment option seems to be the use of MTDs, 
inasmuch as they benefit from the higher patient compliance associated to single-
medicine approaches, and from additional particular advantages derived from their 
single-drug nature. As in the development process of every new chemical entity, the 
development of MTDs is much easier than that of multi-drug approaches, as it involves 
much simpler pharmacokinetic and pharmacodynamic assessment, lower regulatory 
barriers, and simpler clinical trials and drug registration procedures. Also, the increasing 
availability of disease-associated protein-interaction networks will allow the selection of 
a high number of combinations of multiple, in many cases unexpected, protein targets to 
be hit by MTDs, thereby increasing the biological target space and the potential for 
innovation [74]. 
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However, MTDs are also associated to some limitations, mainly the difficulty, but not 
impossibility, for balancing the most appropriate ratio of potencies of the drug at its 
different targets, a problem that in multi-drug therapies can be overcome by adjusting 
the doses of the different drugs. In every case, this is also feasible for MTDs as 
evidenced by the clinical efficacy of many known drugs, retrospectively found to be 
inherently multitarget, but also of some rationally designed MTDs [133]. 
The discovery of novel MTDs can be basically carried out through two different 
procedures that involve the multitarget screening of compound libraries or the rational 
design of MTDs by combination in a single molecule of two pharmacophoric moieties 
with ability to interact with different primary biological targets, the so-called framework 
or pharmacophore combination approach [21,95,130,134-137], which differ not only in 
the way they are carried out but also in the structural complexity of the derived 
multitarget compounds. Not surprisingly, compounds that result from the application of 
the framework combination approach tend to be larger and structurally more complex 
molecules than inherently multitarget compounds found in screening campaigns. The 
difficult-to-refuse argument that human diseases, as complex pathological networks, 
will be better treated by drugs with a complex multitarget pharmacological profile, and 
therefore that complexity must be tackled with complexity, does not necessarily apply, 
however, when structural complexity of MTDs is considered. Indeed, structural 
complexity seems to be detrimental for polypharmacology [136]. Increased structural 
complexity leads to an increased probability of geometrical and electronic 
complementarity mismatch between the drug and the binding site of any given target, 
thereby dramatically diminishing the likelihood of hitting a selective combination of 
targets [4,136,138,139]. The fact that the framework combination approach usually 
leads to large molecules has clear negative implications not only regarding the 
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purported multitarget profile but also the pharmacokinetic profile, as large molecules 
are usually endowed with poor oral absorption. An appropriate selection of the 
combination of targets to be hit as well as the adjustment of the ratio of activities at the 
different targets and druglike physicochemical properties constitute very important 
challenges for medicinal chemists devoted to the development of novel MTDs 
[7,134,135,140]. 
 
5. CONCLUSIONS 
As network biology perspectives are bursting into the drug discovery scenario it is 
becoming increasingly apparent that design of exquisitely selective drugs in the frame 
of the dominant one-disease, one-gene, one-protein, one-drug philosophy is very likely 
to fall short of deriving efficacious and safe new drugs, inasmuch as it is being carried 
out completely disregarding the complex biological context where protein targets and 
drugs act. Indeed, it has been found that human diseases do not usually result from one 
but from several causative factors, and, consequently, there should not be one but 
several relevant protein targets to be hit, which do not work on isolation but in a highly 
interconnected manner by forming complex interaction networks with many other 
cellular components. Very interestingly, it has been also found that most known drugs 
exhibit a multitarget profile, irrespective of the fact that many of them were designed as 
and initially considered to be exquisitely selective toward a particular target, and that 
their multitarget profile, far from leading to toxicity, is instead directly involved in their 
clinical efficacy. Overall, it might be even thought that in most cases the one-disease, 
one-gene, one-protein, one-drug philosophy might be Utopian. Along with this, 
network pharmacology and the notion that the complexity of human disease has to be 
faced up with a complex polypharmacological therapeutic intervention are gaining 
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credence among drug discoverers. In this light, the quite common practice of 
prescribing drug cocktails is now more meaningful than ever, whereas important efforts 
are being made for developing new multitarget therapies, mainly in the form of FDCs or 
MTDs. 
Network biology is still in its infancy, but as our knowledge about interaction networks 
increases, multitarget drug discovery programs, which are currently minor in 
pharmaceutical industry, will certainly spread, slowly replacing single-target-based 
strategies and offering new hopes for the emergence of crucial efficacious and safe new 
treatments for so far intractable diseases and exciting prospects for increased revenues 
of the pharmaceutical industry. 
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